FDA OKs Roche companion diagnostic for Tecentriq combo in TNBC

|About: Roche Holding AG (RHHBY)|By:, SA News Editor

The FDA has approved Roche (OTCQX:RHHBY) unit Ventana's PD-L1 Assay (SP142) as a companion diagnostic to identity suitable triple-negative breast cancer patients for treatment with Tecentriq (atezolizumab) plus Celgene's (NASDAQ:CELG) Abraxane [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel].

The test was launched in 2016 as the primary diagnostic associated with Tecentriq.

Subscribe for full text news in your inbox